These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 17579928)

  • 1. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies.
    Goldberg TE; Weinberger DR
    J Clin Psychiatry; 1996; 57 Suppl 9():62-5. PubMed ID: 8823353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone and cognition: the evolving story.
    Harvey PD
    J Clin Psychiatry; 2003; 64 Suppl 19():33-9. PubMed ID: 14728088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Executive functioning component mechanisms and schizophrenia.
    Kerns JG; Nuechterlein KH; Braver TS; Barch DM
    Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
    Watanabe A; Shibata I; Kato T
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
    Weiss EM; Bilder RM; Fleischhacker WW
    Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognition in schizophrenia: impairments, determinants, and functional importance.
    Bowie CR; Harvey PD
    Psychiatr Clin North Am; 2005 Sep; 28(3):613-33, 626. PubMed ID: 16122570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of correlations between cognitive performances and clinical dimensions of schizophrenia].
    Johnson I; Ben Azouz O; Kebir O; Dellagi L; Amado I; Tabbane K
    Tunis Med; 2009 Oct; 87(10):664-9. PubMed ID: 20187354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
    Barak S; Weiner I
    Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia.
    Rémillard S; Pourcher E; Cohen H
    J Int Neuropsychol Soc; 2008 Jan; 14(1):110-8. PubMed ID: 18078537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychological and activity of daily living script performance in patients with positive or negative schizophrenia.
    Godbout L; Limoges F; Allard I; Braun CM; Stip E
    Compr Psychiatry; 2007; 48(3):293-302. PubMed ID: 17445526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.